Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway

Journal of the National Cancer Institute

Volumn 95, Issue 9, 2003, Pages 652-660

  Fueyo, Juan ^a   Alemany, Ramon ^b   Gomez Manzano, Candelaria ^a   Fuller, Gregory N ^a   Khan, Asadullah ^a   Conrad, Charles A ^a   Liu, Ta Jen ^a   Jiang, Hong ^a   Lemoine, Michael G ^a   Suzuki, Kaori ^c   Sawaya, Raymond ^a   Curiel, David T ^c   Yung, W K Alfred ^a   Lang, Frederick F ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA5 INTEGRIN; GREEN FLUORESCENT PROTEIN; INTEGRIN; RETINOBLASTOMA PROTEIN; TRYPAN BLUE; VIRUS PROTEIN; VIRUS RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTE; CANCER SURVIVAL; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; COXSACKIE VIRUS; CYTOPATHOLOGY; DRUG EFFICACY; DRUG TARGETING; FLOW CYTOMETRY; GENE DELETION; GENE INSERTION; GENE THERAPY; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; SURVIVAL TIME; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS REPLICATION; XENOGRAFT;

EID: 0038288854     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.9.652     Document Type: Article

References (37)

1. Levin VA, Leibel SA, Gutin PH. Neoplasms of the central nervous system. In: DeVita VT, Hellman SJ, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia (PA): Lippincott-Raven; 2001. p. 2100-60.
2. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001;15:1311-33.
3. Sherr CJ. The INK4a/Arf network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7.
4. Whyte P, Williamson NM, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins. Cell 1989;56:67-75.
5. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
6. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-3.
7. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochim Biophys Acta 2002;1575:1-14.
8. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993;73:309-19.
9. Koivunen E, Wang B, Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology 1995;13:265-70.
10. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15:542-6.
11. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001;7:120-6.
12. Jones N, Shenk T. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 1979;17: 683-9.
13. Mahasreshti PJ, Navarro JG, Kataram M, Wang MH, Carey D, Siegal GP, et al. Adenovirus-mediated soluble FLT-1 gene therapy for ovarian carcinoma. Clin Cancer Res 2001;7:2057-66.
14. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, et al. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 1998;4:685-90.
15. Lennette EH. General principles underlying laboratory diagnosis of viral and rickettsial infections. In: Lennette EH, Schmidt NJ, editors. Diagnostic procedures for viral and rickettsial infections. New York (NY): American Public Health Association; 1969. p. 1-63.
16. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, Bruner JM, et al. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 1998;50:1307-15.
17. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, et al. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 1997;89:1036-44.
18. Lal S, Lacroix M, Tofilon P, Fuller GN, Sawaya R, Lang FF. An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 2000;92:326-33.
19. Attia MA, Weiss DW. Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 1966;26:1787-800.
20. Falkeholm L, Grant CA, Magnusson A, Moller E. Xylene-free method for histological preparation: a multicentre evaluation. Lab Invest 2001;81: 1213-21.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
22. Miller CR, Buchsbaum DJ, Reynolds PN, Douglas JT, Gillespie GY, Mayo MS, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998;58:5738-48.
23. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000;18:723-7.
24. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13.
25. Mathias P, Wickham T, Moore M, Nemerow G. Multiple adenovirus serotypes use V integrins for infection. J Virol 1994;68:6811-4.
26. Wickham TJ, Filardo EJ, Cheresh DA, Nemerow GR. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 1994;127:257-64.
27. Wickham TJ. Targeting adenovirus. Gene Ther 2000;7:110-4.
28. Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, King CR, Kovesdi I, et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001;75:11284-91.
29. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-9.
30. Howe JA, Demers GW, Johnson DE, Neugebauer SE, Perry ST, Vaillancourt MT, et al. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol Ther 2000;2:485-95.
31. Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002;1:325-37.
32. Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. Cancer Res 2002;62:3438-47.
33. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B, et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997;71: 8798-807.
34. Wolff G, Worgall S, van Rooijen N, Song WR, Harvey BG, Crystal RG. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997; 71:624-9.
35. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000;81:2605-9.
36. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. Gene Ther 2001;8:1347-53.
37. Lang FF, Gilbert MR, Puduvalli VK, Weinberg J, Levin VA, Yung WK, et al. Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro-oncol 2002;4: 268-77.